Small Molecules of the Month

October 2021
drughunter.com



BMS-986278 | LPA_1

oral LPA_1 GPCR receptor antagonist
Ph. II candidate for IPF (60 mg BID)
from addressing tox. of prior candidate
Journal of Medicinal Chemistry
Bristol Myers Squibb, Princeton, NJ



SJ995973 | CRBN/BET

degrader with simpler CRBN warhead
BRD4 DC50 = 0.87 nM, D_{max} = 99%
from structure-based design
Angewandte Chemie Int. Ed.
Saint Jude Children's Hospital, Memphis, TN



AS-0141 | CDC7

oral, slow-off, selective CDC7 kinase inhibitor
Ph. I candidate for solid tumors
from HTS and PK optimization
Journal of Medicinal Chemistry
Carna Biosciences, Kobe, JP



aficamten | myosin

oral QD myosin inhibitor (IC50 = 1.4 µM)
Ph. II candidate for cardiomyopathy (5-30 mg)
from HTS w/ bovine cardiac muscle myofibrils
Journal of Medicinal Chemistry
Cytokinetics, South San Francisco, CA



CP-628006 | CFTR

CFTR potentiator w/ diff. MoA from ivacaftor
preclinical synergy w/ iva. on G551D-CFTR
from 150k cmpd HTS
British Journal of Pharmacology
Pfizer, Cambridge, UK



reldesemtiv | troponin

second gen. oral troponin activator
Ph. III candidate for ALS (300 mg BID)
from HTS in muscle assay and reducing BP
Journal of Medicinal Chemistry
Cytokinetics, South San Francisco, CA



JNJ-A07 | NS3-NS4B

pan-genotype, pan-serotype dengue virus inh.
high barrier to resistance, efficacious in vivo
from phenotypic antiviral screen
Nature
Janssen Pharmaceutica, Beerse, BE



eliapixant | P2X3

oral P2X3 ion channel antagonist
Ph. II, multiple settings (50-750 mg BID)
from literature P2X3 antagonists
Scientific Reports
Bayer AG, Berlin, DE



repotrectinib | TRK

oral, CNS-penetrant TRK(A-C) kinase inhibitor
Ph. II candidate for solid tumors (160 mg QD)
from literature starting point
Molecular Cancer Therapeutics
Turning Point Therapeutics, San Diego, CA



"compound 10" | TGFβR

tumor specific prodrug of TGFβR inhibitor
QW dosing, improved tumor-to-heart ratio
BMS-986260 prodrug w/ self-immolative link.
Journal of Medicinal Chemistry
Bristol Myers Squibb, Princeton, NJ



venglustat | GCS

potential BIC oral GCS inhibitor
Ph. III in genetic diseases (15 mg QD)
brain-penetrant, allosteric inhibitor
Scientific Reports
Sanofi



maralixibat | IBAT

oral gut-restricted bile acid transporter inh.
approved for cholestatic pruritis in Sep. 2021
repurposed (first patented in 1994)
The Lancet
Mirum / Pfizer / Pharmacia / Searle



"compound 44" | PCSK9

bioavailable bicyclic macrocycle PCSK9 inh.
%F cyno = 2.9, MW 1612, preclinical
from mRNA display screen and SBDD
Journal of Medicinal Chemistry
Merck & Co.



"compound 1" | HPK1

selective inhibitor of unphosphorylated HPK1
non-ATP competitive, IC50 = 1.2 µM
from 700k cmpd HTS for non-ATP comp. inh.
Biochemistry
Janssen R&D, Spring House, PA

HIGHLIGHTS FROM DRUG DISCOVERY ARTICLES PUBLISHED ONLINE | OCT. 2021

drug hunter